| gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis J Bollrath, TJ Phesse, VA von Burstin, T Putoczki, M Bennecke, ... Cancer cell 15 (2), 91-102, 2009 | 1085 | 2009 |
| IL-11 is a crucial determinant of cardiovascular fibrosis S Schafer, S Viswanathan, AA Widjaja, WW Lim, A Moreno-Moral, ... Nature 552 (7683), 110-115, 2017 | 517 | 2017 |
| Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically TL Putoczki, S Thiem, A Loving, RA Busuttil, NJ Wilson, PK Ziegler, ... Cancer cell 24 (2), 257-271, 2013 | 421 | 2013 |
| Stat3: linking inflammation to epithelial cancer-more than a" gut" feeling? A Jarnicki, T Putoczki, M Ernst Cell division 5, 1-15, 2010 | 290 | 2010 |
| Complementarity and redundancy of IL-22-producing innate lymphoid cells LC Rankin, MJH Girard-Madoux, C Seillet, LA Mielke, Y Kerdiles, A Fenis, ... Nature immunology 17 (2), 179-186, 2016 | 243 | 2016 |
| More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer T Putoczki, M Ernst Journal of leukocyte biology 88 (6), 1109-1117, 2010 | 167 | 2010 |
| Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies FH Tan, TL Putoczki, SS Stylli, RB Luwor OncoTargets and therapy, 635-645, 2019 | 161 | 2019 |
| TCF-1 controls ILC2 and NKp46+ RORγt+ innate lymphocyte differentiation and protection in intestinal inflammation LA Mielke, JR Groom, LC Rankin, C Seillet, F Masson, T Putoczki, ... The Journal of Immunology 191 (8), 4383-4391, 2013 | 143 | 2013 |
| Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer CN Johnstone, A Chand, TL Putoczki, M Ernst Cytokine & growth factor reviews 26 (5), 489-498, 2015 | 133 | 2015 |
| mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice S Thiem, TP Pierce, M Palmieri, TL Putoczki, M Buchert, A Preaudet, ... The Journal of clinical investigation 123 (2), 2013 | 130 | 2013 |
| Interleukin-11 links oxidative stress and compensatory proliferation T Nishina, S Komazawa-Sakon, S Yanaka, X Piao, DM Zheng, JH Piao, ... Science signaling 5 (207), ra5-ra5, 2012 | 118 | 2012 |
| Mitophagy in intestinal epithelial cells triggers adaptive immunity during tumorigenesis PK Ziegler, J Bollrath, CK Pallangyo, T Matsutani, Ö Canli, T De Oliveira, ... Cell 174 (1), 88-101. e16, 2018 | 111 | 2018 |
| STAT3-activating cytokines: a therapeutic opportunity for inflammatory bowel disease? PM Nguyen, TL Putoczki, M Ernst Journal of interferon & cytokine research 35 (5), 340-350, 2015 | 109 | 2015 |
| NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease H Tye, CH Yu, LA Simms, MR de Zoete, ML Kim, M Zakrzewski, ... Nature communications 9 (1), 3728, 2018 | 103 | 2018 |
| JAK-STAT signalling pathway in cancer AJ Brooks, T Putoczki Cancers 12 (7), 1971, 2020 | 100 | 2020 |
| Molecular pathways: IL11 as a tumor-promoting cytokine—translational implications for cancers M Ernst, TL Putoczki Clinical Cancer Research 20 (22), 5579-5588, 2014 | 95 | 2014 |
| IL-11 signaling as a therapeutic target for cancer TL Putoczki, M Ernst Immunotherapy 7 (4), 441-453, 2015 | 93 | 2015 |
| Structural understanding of interleukin 6 family cytokine signaling and targeted therapies: focus on interleukin 11 RD Metcalfe, TL Putoczki, MDW Griffin Frontiers in immunology 11, 540177, 2020 | 77 | 2020 |
| The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma R Coulson, SH Liew, AA Connelly, NS Yee, S Deb, B Kumar, AC Vargas, ... Oncotarget 8 (12), 18640, 2017 | 76 | 2017 |
| The role of STAT3 signaling in mediating tumor resistance to cancer therapy F H Tan, T L Putoczki, S S Stylli, R B Luwor Current Drug Targets 15 (14), 1341-1353, 2014 | 76 | 2014 |
